Phase 1 data presented in an oral plenary session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026) in Barcelona, Spain, showed deep and durable responses in patients with FGFR3-altered urothelial cancer (UC) and head and neck squamous cell carcinoma (HNSCC). As of the data cutoff in the ongoing study, 6 of 10 evaluable patients with FGFR3 activating alterations treated at doses of ≥3.3 mg/kg had responded, including 3 of 5 with UC and 3 of 3 with HPV-positive HNSCC.








